TOKYO -- Japanese drugmaker Shionogi announced a partnership with a Chinese counterpart on Thursday to promote its oral COVID-19 treatment in China, as the country grapples with a surging outbreak.
Pharmaceuticals
Drugmaker Shionogi inks deal to market COVID pill in China
Agreement with Sino Bio unit comes a month after antiviral drug's approval in Japan
Shionogi's Xocova is Japan's first locally developed oral treatment for COVID-19. (Nikkei montage)
Read Next
Latest on Pharmaceuticals
